First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.
Christophe Le Tourneau(Institut Curie), Marie Dutreix(Centre National de la Recherche Scientifique), Célèste Lebbé(Inserm), Jean‐Marc Cosset(Institut Curie), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), E. Maubec(Inserm), Thomas Jouary(Hôpital Saint-André), Flavien Devun(HiFiBiO Therapeutics (France)), Pierre Bey(Institut Curie), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Jian‐Sheng Sun(HiFiBiO Therapeutics (France)), Laurent Mortier, L. Thomas(University of Liverpool), Bernard Asselain(UniCancer Group), Marie‐Françoise Avril(Délégation Paris 7), Brigitte Dréno(Nantes Université), M. Marty(Hôpital Saint-Louis), Youlia Kirova(Institut Curie)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k